TEST REQUIREMENT CHANGE
Amyloid Protein Identification, Paraffin, LC-MS/MS
Order Code: AMPIP
Fee Code: TBD (CPT 88313, (82542, 88380))
Reference Lab: Mayo AMPIP
Effective May 11, 2026, Mayo Clinic Laboratories test, AMPIP, testing of tenosynovial specimens is only available on patients aged ≥75 years. This approach is based on current evidence regarding ATTR amyloidosis. Tenosynovial ATTR deposition is considered a potential early marker (risk factor) for subsequent cardiac involvement; however, it does not in itself warrant treatment. Only a minority of patients with tenosynovial ATTR go on to develop cardiac ATTR, and progression—when it occurs—may take many years to decades. By restricting testing for this specimen type to a higher-risk age group, we aim to prioritize tenosynovial cases with the greatest likelihood of clinically actionable cardiac involvement, while also ensuring capacity for other specimen types with more immediate clinical impact. Regardless of amyloid type, the presence of tenosynovial amyloid raises the possibility of underlying cardiac amyloidosis (Westin O, et al. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977). Clinicopathologic correlation is recommended, with consideration of cardiology consultation as clinically indicated.